1. Overview of BCR-ABL1
- Genes involved:
- BCR (Breakpoint Cluster Region) – chromosome 22q11
- ABL1 (Abelson Murine Leukemia viral oncogene homolog 1) – chromosome 9q34
- Fusion: t(9;22)(q34;q11) → Philadelphia chromosome
- Result: Constitutively active ABL1 tyrosine kinase → uncontrolled proliferation, reduced apoptosis
2. Tumor Associations
| Tumor | Notes |
|---|---|
| Chronic Myeloid Leukemia (CML) | >95% of cases; hallmark of disease |
| Acute Lymphoblastic Leukemia (ALL) | 20–30% of adult ALL; ~3% pediatric ALL |
| Acute Myeloid Leukemia (rare) | Rare, poor prognosis |
3. Mechanism of Oncogenesis
- Constitutive BCR-ABL1 kinase activity → activates multiple signaling pathways:
- RAS–RAF–MEK–ERK → proliferation
- PI3K–AKT → survival
- STAT5 → transcription of anti-apoptotic genes
- Result: Myeloid or lymphoid cells proliferate uncontrollably → leukemia
4. Clinical Implications
- CML Phases: Chronic → Accelerated → Blast crisis
- Prognosis:
- Excellent with early tyrosine kinase inhibitor (TKI) therapy
- Blast crisis has poor prognosis without therapy
5. Targeted Therapy
| Drug | Class | Notes |
|---|---|---|
| Imatinib | First-generation TKI | Binds ATP site of BCR-ABL1; revolutionized CML therapy |
| Dasatinib | Second-generation TKI | More potent; inhibits Src family kinases too |
| Nilotinib | Second-generation TKI | More selective; requires fasting |
| Bosutinib | Second-generation TKI | Less off-target kinase activity |
| Ponatinib | Third-generation TKI | Effective against T315I resistance mutation |
Key Points:
- Molecular monitoring of BCR-ABL1 transcript (qPCR) guides therapy
- Resistance mechanisms:
6. Adverse Effects of BCR-ABL1 TKIs
- Common: Fatigue, nausea, diarrhea, cytopenias
- Serious: Cardiovascular events (nilotinib, ponatinib), pleural effusions (dasatinib), hepatotoxicity
Summary
- BCR-ABL1 is a constitutively active tyrosine kinase fusion driving CML and some ALL
- TKIs targeting BCR-ABL1 transformed prognosis from fatal to chronic disease
- Molecular testing is essential for diagnosis, therapy selection, and monitoring